Volume 8, Number 5—May 2002
Research
Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children: Implications for the Use of Heptavalent Pnemococcal Conjugate Vaccine
Paola Marchisio*, Susanna Esposito*, Gian Carlo Schito†, Anna Marchese†, Roberta Cavagna*, Nicola Principi*
, and the Hercules Project Collaborative Group
, and the Hercules Project Collaborative Group
Table 3
Antibiotic resistance pattern of Streptococcus pneumoniae strains, 13 Italian cities, April 15–June 15, 2000
| Antibiotic | Resistant strains (%) |
|---|---|
| Penicillin | 22 (9.1%) |
| Amoxicillin | 0 |
| Amoxicillin-clavulanate | 0 |
| Cefotaxime | 9 (3.7) |
| Ceftriaxone | 8 (3.3) |
| Meropenem | 12 (4.9) |
| Azithromycin | 126 (52.1) |
| Clarithromycin | 126 (52.1) |
| Erythromycin | 126 (52.1) |
| Tetracyclin | 74 (30.6) |
| Thrimethoprim-sulphamethoxazole | 58 (23.9) |
| Rifampicin | 0 |
| Chloramphenicol | 26 (10.7) |
1The Hercules Project Collaborative Group includes: F. Schettini, D. De Mattia (Bari, Italy); G. P. Salvioli, G. Faldella (Bologna, Italy); G. Caramia, E. Ruffini (Ancona, Italy); E. Reali (Cinisello Balsamo, Italy); R. Longhi (Como, Italy); G. Bona (Novara, Italy); A. Guarino, F. Albano (Napoli, Italy); R. Malvicini (Fidenza, Italy); L. Ziino (Palermo, Italy); I. Barberi, T. Corona (Messina, Italy); P. Pusceddu (Cagliari, Italy); T. Meloni (Sassari, Italy); G. Saggese, and M. Migliaccio (Pisa, Italy).
Page created: April 18, 2012
Page updated: April 18, 2012
Page reviewed: April 18, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.